Skip to main navigation

Skip to Content

Home
About Us
Clinical Pipeline & Technology
- ANA001
- Gemcabene
- NB-01
- NB-02
Investors & News
Contact Us

Press Releases

Keyword Search

Year

Nov 15, 2021

NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results

Nov 04, 2021

NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer

Oct 13, 2021

NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID-19

Oct 05, 2021

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

Oct 01, 2021

NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering

Aug 16, 2021

NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results

Jul 12, 2021

NeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors

May 17, 2021

NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results

Apr 15, 2021

NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update

Mar 24, 2021

NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene

Pagination

Current page 1
Page 2
Next page
Last page

Print

RSS Feeds

E-mail Alerts

IR Contacts

LinkedIn
Contact Us
Terms of Use
Privacy Policy

©2021 NeuroBo Pharmaceuticals, Inc.